Trial Profile
The effect of Januvia (sitagliptin) on oxidative stress in obese type 2 diabetic subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 02 Feb 2022 Status changed from active, no longer recruiting to completed.
- 28 Jun 2012 Results assessing anti-inflammatory outcomes published in the Journal of Clinical Endocrinology and Metabolism.
- 05 Jun 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.